Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, September 29, 2014

The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence

The Use of Disease-Modifying Therapies in Multiple Sclerosis:
Principles and Current Evidence 

Dear Colleagues,

The Consortium of MS Centers collaborated with the seven other member organizations of the MS Coalition to develop a paper that summarizes current evidence about disease modification in multiple sclerosis and provides support for broad access to U.S. Food and Drug Administration-approved MS disease-modifying therapies for people with MS in the United States. The paper was reviewed by nine external reviewers and subsequently endorsed by all eight MS Coalition organizations.
The document will serve as a valuable tool for professionals engaged in MS care. A summary document is currently in development for general audiences and once completed, will be distributed to all of our members.
Please find the two versions of the document-a full color and a grey scale version for your review and download. Please feel free to share with others!

Consortium of Multiple Sclerosis Centers

 Keep CURRENT and up to date, 
Sign-Up for our email

No comments: